natgillin/translations-raw huggingface dataset:
Two thirds of respondents considered that JAMRAI provided effective support; and that the training provided by the Commission on the One Health approach was beneficial. 
Dve tretjini vprašanih je menilo, da skupni ukrep JAMRAI zagotavlja uspešno podporo in da je bilo usposabljanje, ki ga je zagotovila Komisija o pristopu „eno zdravje”, koristno.
Three quarters of respondents considered the One Health Networks were useful. 
Tri četrtine vprašanih so menile, da so mreže „eno zdravje” koristne.
Their views on the CommissionŐs guidance on the prudent use of antimicrobials, for human and animal use, were similarly positive. 
Podobno pozitivna so bila njihova stališča o smernicah Komisije za preudarno uporabo antimikrobikov, ki se uporabljajo pri ljudeh in živalih.
Table 1 Đ Measures funded from the Health Programme to support AMR policies 17 Action Budget (000 euro) Summary description Joint Action on Antimicrobial Resistance (JAMRAI) 4 200 JAMRAI16 aims at fostering synergies between EU Member States by developing and implementing effective One Health policies and reducing Health care associated infections; It has 9 work packages and 19 Member States, and provides a platform for exchange of experiences and developing best practices. 
Tabela 1 – Ukrepi, ki se financirajo iz zdravstvenega programa v podporo politikam na področju protimikrobne odpornosti Vir: Evropsko računsko sodišče 17 Ukrep Proračun (v tisočih EUR) Kratek opis Skupni ukrep na področju protimikrobne odpornosti (JAMRAI) 4 200 Namen ukrepa JAMRAI16 je spodbuditi sinergije med državami članicami EU tako, da se razvijajo in izvajajo uspešne politike po načelu „eno zdravje” ter zmanjša število okužb, povezanih z zdravstveno oskrbo.
WHO 600 This action supports Member States to develop and implement national One Health action plans. 
SZO 600 Ta ukrep podpira države članice pri pripravi in izvajanju nacionalnih akcijskih načrtov „eno zdravje”.
OECD 340 OECD assessed the economic burden of AMR. 
OECD 340 OECD je ocenil gospodarsko breme protimikrobne odpornosti.
It calculated that actions to reduce AMR were good investments that would soon more than pay for themselves. 
Izračunal je, da so ukrepi za zmanjšanje protimikrobne odpornosti dobra naložba, za katero bodo stroški kmalu več kot povrnjeni.
16 See EU JAMRAI vision / mission. The Commission-funded Joint Action on Antimicrobial Resistance (JAMRAI) faced challenges while facilitating cooperation between Member States 23 JAMRAI started on 1 September 2017, and will run for 36 months. 
Pri skupnem ukrepu na področju protimikrobne odpornosti (JAMRAI), ki ga financira Komisija, so se pojavili izzivi v zvezi z omogočanjem sodelovanja med državami članicami 23 Skupni ukrep JAMRAI se je začel izvajati 1. septembra 2017 in bo trajal 36 mesecev.
We found that most JAMRAI work packages17 were generally on track to produce their agreed deliverables and that JAMRAI provides a good platform for exchanges of experiences and best practices between the 19 participating Member States18. 
Sodišče je ugotovilo, da je večina delovnih sklopov v okviru ukrepa JAMRAI17 v splošnem na dobri poti, da se dosežejo dogovorjeni rezultati, in da je ta ukrep dobra platforma za izmenjavo izkušenj in najboljših praks med 19 sodelujočimi državami članicami18.
24 However, JAMRAI faced some challenges. 
24 Vendar se pri skupnem ukrepu JAMRAI pojavljajo nekateri izzivi.
It did not have a complete One Health approach, as there were no environmental authorities involved in Work Packages, and there was a relatively low participation from Member State veterinary authorities. 
Pri njem ni bil uporabljen popoln pristop „eno zdravje”, saj pri delovnih sklopih niso sodelovali okoljski organi, sodelovanje veterinarskih organov držav članic pa je bilo sorazmerno skromno.
Work Packages 4 (for integration in national policies and sustainability) and 7 (for the appropriate use of antimicrobials in humans and animals) were experiencing delays. 
Pri delovnih sklopih 4 (za vključevanje v nacionalne politike in trajnostnost) in 7 (za ustrezno uporabo antimikrobikov pri ljudeh in živalih) je prihajalo do zamud.
Furthermore, JAMRAIŐs overall success will depend largely on actions subsequently taken by the Member States to actually implement the solutions developed by the work packages. 
Poleg tega bo splošen uspeh skupnega ukrepa JAMRAI pretežno odvisen od ukrepov, ki jih bodo države članice sprejele za dejansko izvajanje rešitev, ki so bile razvite v okviru delovnih sklopov.
The WHO project had not supported the targeted numbers of Member States in itsŐ first year of operation 25 The WHO project began in May 2018 and is scheduled to run for three years, to help Member States develop and implement national One Health action plans. 
Projekt SZO v prvem letu delovanja ni podprl ciljnega števila držav članic 25 Projekt SZO se je začel maja 2018 in naj bi trajal tri leta, njegov namen pa je pomagati državam članicam razviti in izvajati nacionalne akcijske načrte „eno zdravje”.
The Commission arranged for WHO to present the project to Member States in the EU Health Security Committee in June 2018 and in the One Health Network. 
Komisija je uredila, da je SZO projekt predstavila državam članicam v okviru Odbora EU za zdravstveno varnost junija 2018 in v okviru mreže „eno zdravje”.
This project was behind schedule at the time of the audit and had not supported the targeted numbers of Member States for its various sub-objectives (a total of four instead of 812 for each sub-objective). 
Ta projekt je bil v času revizije v zaostanku in ni podpiral ciljnega števila držav članic pri svojih različnih podciljih (skupaj štiri namesto osem do dvanajst za vsak podcilj).
18 Plus Norway. 
18 In Norveško.
It showed that actions to reduce AMR were relatively cheap, cost-effective and feasible (see Box 2). 
Pokazalo je, da so ukrepi za zmanjšanje protimikrobne odpornosti razmeroma poceni, stroškovno učinkoviti in izvedljivi (glej okvir 2).
Box 2 OECD report findings - an invitation for action The 2018 OECD report ŇStemming the superbug tide Đ Just a few dollars moreÓ indicates that three out of four deaths from superbug infections could be averted by spending just $ USD 2 per person a year on measures as simple as facilitating handwashing and more prudent prescription of antibiotics. 
19 Okvir 2 Ugotovitve v poročilu organizacije OECD – povabilo k ukrepanju Poročilo organizacije OECD z naslovom Stemming the superbug tide – Just a few dollars more kaže, da bi bilo mogoče tri od štirih smrti, ki jih povzročijo okužbe z multirezistentnimi bakterijami, preprečiti zgolj z dvema ameriškima dolarjema na osebo letno, če bi se namenila za tako preproste ukrepe, kot je omogočanje umivanja rok in preudarnejše predpisovanje antibiotikov.
Up to 1.6 million lives would be saved by 2050 across the 33 countries included in the OECD analysis, by using measures such as: promoting hospital hygiene; reducing over-prescription of antibiotics; improving antimicrobial stewardship programmes; mass media campaigns; and the use of rapid tests to detect whether an infection is bacterial or viral. 
Do leta 2050 bi se rešilo 1,6 milijona življenj v 33 državah, vključenih v analizo organizacije OECD, z uporabo ukrepov, kot so: spodbujanje bolnišnične higiene, zmanjšanje prekomernega predpisovanja antibiotikov, izboljšanje programov usmerjanja uporabe antimikrobikov, medijske kampanje in uporaba hitrih testov za ugotavljanje, ali je okužba bakterijska ali virusna.
OECD considers that investments in these measures could pay for themselves within one year and produce savings of about $ 1.5 USD for every dollar invested afterwards. 
OECD meni, da bi se naložbe v te ukrepe lahko povrnile v enem letu in bi se z njimi ustvarili prihranki v višini približno 1,5 USD za vsak pozneje naložen ameriški dolar.
Combining these measures in a coherent way would yield even higher benefits and savings. 
Z usklajenim kombiniranjem teh ukrepov bi se dosegli še večji koristi in prihranki.
27 In this context we note that health is not a strategic investment priority for the Structural Funds in the current programming period, but that the Structural Funds are used for the investments in health. 
27 V zvezi s tem Sodišče ugotavlja, da zdravje v okviru strukturnih skladov ni prioriteta za strateške naložbe v sedanjem programskem obdobju, vendar se strukturni skladi uporabljajo za naložbe v zdravje.
A Commission-funded study20 found that 7 404 health projects were funded by the Structural Funds between 2014-2018, with a total allocation of Ű8 billion. 
V študiji, ki jo je financirala Komisija,20 je bilo ugotovljeno, da so se med leti 2014 in 2018 iz strukturnih skladov financirali 7 404 zdravstveni projekti, za katere so skupna dodeljena sredstva znašala 8 milijard EUR.
Only two of these projects were identified as having specific AMR objectives. 
Samo za dva od teh projektov je bilo ugotovljeno, da imata specifične cilje v zvezi s protimikrobno odpornostjo.
The study identified that the intended inclusion of the EU Health Programme in the Structural Funds under ESF+ was an opportunity to achieve further synergies between funding instruments and investments in cross-sectoral collaboration21. 
V študiji je bilo ugotovljeno, da je načrtovana vključitev zdravstvenega programa EU v strukturne sklade v okviru ESS+ priložnost za doseganje 19 Stemming the superbug tide - Just a few dollars more, OECD, 2018.
20 ESI Funds for Health Đ Investing for a healthy and inclusive EU Đ Final Report, Milieu Law and Policy Consulting, 2019. 
20 ESI Funds for Health – Investing for a healthy and inclusive EU – Final Report, Milieu Law and Policy Consulting, 2019.
ECDC actions provided valuable support to the Commission and Member States in fighting AMR 28 The ECDC performs a range of AMR related tasks. 
Z ukrepi centra ECDC se je Komisiji in državam članicam zagotovila dragocena podpora v boju zoper protimikrobno odpornost 28 ECDC opravlja vrsto nalog, povezanih s protimikrobno odpornostjo.
It coordinates surveillance of AMR, antimicrobial consumption and healthcare-associated infections with three networks, i.e. the European Antimicrobial Resistance Surveillance Network (EARS-Net); the European Surveillance of Antimicrobial Consumption Network (ESAC-Net) and the Healthcare-Associated Infections surveillance Network (HAI-Net), under the AMR and Healthcare-Associated Infections (ARHAI) programme. 
Usklajuje nadzor nad njo, nad porabo antimikrobikov in okužbami, povezanimi z zdravstveno oskrbo, s pomočjo treh mrež, tj. Evropske mreže za nadzor protimikrobne odpornosti (EARS-Net), Evropske mreže za spremljanje porabe protimikrobnih zdravil (ESAC-Net) in mreže za spremljanje okužb, povezanih z zdravstveno oskrbo, v okviru programa o protimikrobni odpornosti in okužbah, povezanih z zdravstveno oskrbo.
These surveillance networks provide key scientific information in a harmonised format, which is used for ECDCŐs scientific advice, training, country visits and awareness raising activities. 
S temi nadzornimi mrežami se v usklajeni obliki zagotovijo ključne znanstvene informacije, ki se uporabijo za znanstvene nasvete centra ECDC, usposabljanja, obiske držav in dejavnosti ozaveščanja.
The ECDC uses information from these networks to contribute data, on behalf of EU / EEA countries to the WHO. 
ECDC z uporabo informacij iz teh mrež v imenu držav EU/EGP prispeva podatke organizaciji SZO.
29 ECDC performs country visits aimed at providing assistance to national authorities. 
29 ECDC v državah opravlja obiske, katerih namen je zagotavljanje pomoči nacionalnim organom.
Between 2006 and 2017, ECDC conducted 25 such visits devoted to the use of antimicrobial agents in human medicine. 
Med letoma 2006 in 2017 je opravil 25 takih obiskov, ki so bili posvečeni uporabi protimikrobnih sredstev v humani medicini.
Since the launch of the EU One Health Action Plan in 2017, ECDC and the Commission perform joint country visits in a One Health approach, combining human and animal health. 
ECDC in Komisija od začetka izvajanja akcijskega načrta EU „eno zdravje” leta 2017 izvajata skupne obiske držav v okviru pristopa „eno zdravje”, ki združuje zdravje ljudi in živali.
By April 2019 there had been six such visits (compared with an initial plan to do six per year), as most Member State have not requested them. 
Do aprila 2019 je bilo takih obiskov šest (v primerjavi z v začetku načrtovanimi šestimi obiski na leto), saj večina držav članic zanje ni zaprosila.
The replies to our survey indicated that these visits had a significant impact on the development of AMR actions by the Member States concerned. 
Odgovori na anketo Sodišča so pokazali, da so ti obiski pomembno vplivali na razvoj ukrepov v zvezi s protimikrobno odpornostjo v zadevnih državah članicah.
30 We noted that ECDC received an increasing number of AMR-related requests for assistance. 
30 Sodišče je ugotovilo, da je ECDC prejemal vedno več prošenj za pomoč, povezanih s protimikrobno odpornostjo.
It postponed activities when more important requests took priority. 
Dejavnosti je prelagal, kadar so dobile prednost pomembnejše prošnje.
We consider that ECDCŐs activities inform both the Commission and Member States, while noting the increasing risk that ECDC cannot perform important AMR work on time. 
Sodišče verjame, da se z dejavnostmi centra ECDC obveščajo Komisija in države članice, opaža pa vedno večje tveganje, da ECDC ne bo zmogel pravočasno izvajati pomembnega dela v zvezi s protimikrobno odpornostjo.
There were gaps in information on outcomes and surveillance of AMR 31 The CommissionŐs overall objective is to make the EU a best practice region for AMR and antimicrobial consumption. 
V informacijah o izidih in nadzoru v zvezi s protimikrobno odpornostjo so bile vrzeli 31 Splošni cilj Komisije je, da EU postane regija najboljše prakse, kar zadeva protimikrobno odpornost in porabo antimikrobikov.
In the context of its EU action plan, it thus requested the EU agencies (ECDC, EFSA and EMA) to produce a scientific opinion on outcome indicators for AMR One Health Action that could use existing surveillance data. 
V okviru akcijskega načrta EU je zato pozvala agencije EU (ECDC, EFSA in EMA), naj pripravijo znanstveno mnenje o kazalnikih izidov za ukrepe na področju protimikrobne odpornosti po načelu „eno zdravje”, pri katerih bi se lahko uporabili obstoječi podatki o nadzoru.
Those indicators should assist Member States in monitoring their progress in reducing the use of antimicrobials and AMR in humans and food-producing animals, and to set targets to decrease risks of AMR. 20 
Ti kazalniki bi morali pomagati državam članicam spremljati njihov napredek pri zmanjševanju uporabe antimikrobikov in protimikrobne odpornosti pri ljudeh in pri živalih za proizvodnjo živil ter določiti cilje zmanjšanja tveganj, povezanih s protimikrobno odpornostjo.
32 Following this request, the agencies produced a Joint Scientific Opinion on outcome indicators in October 201722. At the time of the audit (April 2019), we found that the status of these outcome indicators was uncertain, and that they were not consistently used by the Member States we visited, or by the Commission, to monitor progress. 
32 Agencije so na podlagi tega poziva oktobra 2017 pripravile skupno znanstveno mnenje o kazalnikih izidov.22 Sodišče je ob reviziji (aprila 2019) ugotovilo, da je stanje v zvezi s temi kazalniki izidov negotovo in da jih države, ki jih je obiskalo, pa tudi Komisija, niso dosledno uporabljale za spremljanje napredka.
Surveillance of healthcare associated infections was incomplete despite EU legal requirements 33 There is consistent evidence23 that healthcare associated infections (HAIs) are the primary source of infection by AMR in humans in Europe. 
Nadzor nad okužbami, povezanimi z zdravstveno oskrbo, je bil kljub pravnim zahtevam EU nepopoln 33 Obstajajo trdni dokazi23, da so v Evropi okužbe, povezane z zdravstveno oskrbo, pri ljudeh glavni vir okužb zaradi protimikrobne odpornosti.
According to ECDC data, transmission of resistant bacteria in hospitals and other healthcare settings is a serious issue since almost nine million HAIs occur in the EU each year. 
Po podatkih centra ECDC je prenos odpornih bakterij v bolnišnicah in drugih zdravstvenih okoljih resen problem, saj v EU vsako leto pride do skoraj devet milijonov okužb, povezanih z zdravstveno oskrbo.
This study showed that the contribution of various antibiotic-resistant bacteria to the overall burden varies greatly between countries. 
Ta študija je pokazala, da se med državami zelo razlikuje prispevek različnih bakterij, odpornih proti antibiotikom, k skupnemu bremenu.
The ECDC has identified that in five Member States, more than half of healthcare associated infections in acute care hospitals were caused by resistant bacterial pathogens (see Figure 5). 
ECDC je ugotovil, da v petih državah članicah več kot polovico okužb, povezanih z zdravstveno oskrbo, v bolnišnicah za akutno oskrbo povzročijo odporni bakterijski patogeni (glej sliko 5).
21 22 ECDC, EFSA and EMA Joint Scientific Opinion on a list of outcome indicators as regards surveillance of antimicrobial resistance and antimicrobial consumption in humans and food-producing animals, October 2017. 
22 ECDC, EFSA and EMA Joint Scientific Opinion on a list of outcome indicators as regards surveillance of antimicrobial resistance and antimicrobial consumption in humans and food-producing animals, oktober 2017.
23 Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis, A. Cassini, The Lancet, January 2019. 
23 Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis, A. Cassini, The Lancet, januar 2019.
Figure 5 Đ AMR in HAI from acute care hospital according to the data collected by the ECDC In 2018, ECDC developed a composite index of AMR in Healthcare Associated Infections from acute care hospitals. 
Slika 5 – Protimikrobna odpornost pri okužbah, povezanih z zdravstveno oskrbo, v bolnišnicah za akutno oskrbo glede na podatke, ki jih je zbral center ECDC ECDC je leta 2018 razvil sestavljen indeks za protimikrobno odpornost pri okužbah, povezanih z zdravstveno oskrbo, v bolnišnicah za akutno oskrbo.
Resistant isolates (%) <5 5 to <20 20 to <35 35 to <50 >=50 No data Not invited Non-visiblecountries Liechtenstein Luxembourg Malta Source: ECDC, 2018; Adapted from: Suetens C, et al. 
Odporni izolati (v %) <5 5 to <20 20 to <35 35 to <50 >=50 Ni podatkov Ni povabila Ne-vidne države Lihtenštajn Luksemburg Malta Vir: ECDC, 2018; prirejeno po: Suetens C, et al.
2018;23(46):pii=1800516. 
2018; 23 (46): PII = 1 800 516.
34 In its Recommendation of 9 June 200924 the Council already recommended Member States to engage in prevalence surveys and surveillance of targeted infection types, using where appropriate ECDC recommended surveillance methods and indicators agreed at Community level. 
34 Svet je v svojem priporočilu z dne 9. junija 200924 že priporočil državam članicam, naj izvajajo raziskave o razširjenosti in nadzor ciljnih vrst okužb, pri tem pa po potrebi uporabijo metode nadzora, ki jih priporoča center ECDC, in kazalnike, dogovorjene na ravni Skupnosti.
However, the surveillance of HAIs is a complex and resource intensive exercise, in particular because it relies on patient information that needs to be collected at the hospital level. 
Vendar je izvajanje nadzora nad okužbami, povezanimi z varnostno oskrbo, kompleksno in zanj je potrebnih veliko virov, zlasti zato, ker se opira na informacije o pacientih, ki jih je treba zbrati na ravni bolnišnice.
It also requires extensive data validation. 
Zanj je potrebno tudi obsežno potrjevanje podatkov.
35 We found that HAI surveillance data for the EU is incomplete. 
35 Sodišče poudarja, da so podatki o nadzoru nad okužbami, povezanimi z zdravstveno oskrbo, za EU nepopolni.
Involvement in ECDC surveillance25 ranges from six Member States that participate in all five modules of ECDCŐs HAI-Net surveillance network to three Member States that participate in one 24 Council Recommendation of 9 June 2009 on patient safety, including the prevention and control of healthcare associated infections (2009/C 151/01). 
Sodelovanje pri nadzoru, ki ga usklajuje center 24 Priporočilo Sveta z dne 9. junija 2009 o varnosti pacientov, vključno s preprečevanjem in obvladovanjem okužb, povezanih z zdravstveno oskrbo (2009/C 151/01). 22
The incompleteness of the surveillance data is likely to slow down actions against AMR. 
Nepopolnost podatkov o nadzoru bo verjetno upočasnila ukrepanje zoper protimikrobno odpornost.
36 The environment is one of the pillars of the One Health approach to AMR, together with human health and veterinary issues. 
36 Okolje je ob zdravju ljudi in veterinarskih zadevah eden od stebrov pristopa k protimikrobni odpornosti po načelu „eno zdravje”.
We note that better addressing the role of the environment was a specific objective under the CommissionŐs current One Health Action Plan. 
Sodišče ugotavlja, da je bilo boljše obravnavanje vloge okolja poseben cilj sedanjega akcijskega načrta Komisije „eno zdravje”.
There is little information targeting the process of transmission of AMR through the environment, when compared with human health and animal health sectors. 
V primerjavi s sektorjema zdravja ljudi in zdravja živali je malo informacij, ki bi zadevale proces prenosa protimikrobne odpornosti v okolju.
The environmental sector is not specifically included in the JAMRAI Work Packages, nor under the various EU surveillance systems for AMR. 
Okoljski sektor ni posebej vključen v delovne sklope ukrepa JAMRAI, pa tudi ne v različne nadzorne sisteme EU za protimikrobno odpornost.
In 2019 the Commission adopted a communication26 on a ŇEuropean Union strategic approach to pharmaceuticals and the environmentÓ, which included the objective to identify actions to combat AMR. 
Komisija je leta 2019 sprejela sporočilo26 z naslovom Strateški pristop Evropske unije k farmacevtskim izdelkom v okolju, v katerega je vključila tudi cilj o opredelitvi ukrepov za bolj zoper protimikrobno odpornost.
We also note that a scientific report27 by EFSA from 2019 suggested the monitoring of AMR in the environment. 
Sodišče ugotavlja tudi, da je bilo v znanstvenem poročilu iz leta 201927, ki ga je izdelala agencija EFSA, priporočeno spremljanje protimikrobne odpornosti v okolju.
The prudent use of veterinary antimicrobials in the Member States has improved 37 The excessive use of veterinary antimicrobials, and AMR in animals and food, are vectors in the development of AMR in human health, and are areas where the EU has clear competences (see paragraph 14). 
Uporaba antimikrobikov, namenjenih za veterinarsko medicino, je postala v državah članicah preudarnejša 37 Prekomerna uporaba antimikrobikov v veterinarski medicini in protimikrobna odpornost pri živalih in v živilih sta vektorja pri razvoju protimikrobne odpornosti pri zdravju ljudi in področji, na katerih ima EU jasne pristojnosti (glej odstavek 14).
We therefore examined whether there was evidence that veterinary antimicrobials were better used and whether the EU rules on the monitoring and reporting of AMR in zoonotic and commensal bacteria were applied well in practice. 
Sodišče je zato preučilo, ali obstajajo dokazi, da so bili antimikrobiki za veterinarsko medicino bolje uporabljani, in ali so bila pravila EU o spremljanju protimikrobne odpornosti pri zoonotskih in komenzalnih bakterijah ter poročanju o njej v praksi dobro uporabljena.
We also reviewed to what extent new EU rules for veterinary medicinal products and medicated feed address weaknesses. 
Pregledalo je tudi, koliko so v novih pravilih EU o zdravilih za uporabo v veterinarski medicini in medicirani krmi odpravljene slabosti.